Elanco Animal Health (ELAN) reported Q3 FY2025 results characterized by strong revenue growth but a sharp net loss reversing the prior year’s significant divestiture gain.
Financial Performance (9 Months Ended 9/30/2025): Total revenue increased 4% YoY to \(3.57B, with Q3 revenue up 10% to \)1.14B, driven by new product launches. However, Net Income plummeted to \(44M (YTD) from \)346M in 2024. Q3 reported a net loss of (\(34)M, compared to \)364M income in Q3 2024, primarily due to the absence of the $640M gain recognized on the Aqua business divestiture last year. Gross Margin improved slight
...